Logo image of RPTX

REPARE THERAPEUTICS INC (RPTX) Stock Overview

NASDAQ:RPTX - US7602731025 - Common Stock

1.67 USD
+0.01 (+0.6%)
Last: 8/29/2025, 8:00:02 PM

RPTX Key Statistics, Chart & Performance

Key Statistics
52 Week High4.07
52 Week Low0.89
Market Cap71.74M
Shares42.96M
Float38.99M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.55
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-19 2020-06-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


RPTX short term performance overview.The bars show the price performance of RPTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

RPTX long term performance overview.The bars show the price performance of RPTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RPTX is 1.67 USD. In the past month the price increased by 11.33%. In the past year, price decreased by -42.61%.

REPARE THERAPEUTICS INC / RPTX Daily stock chart

RPTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About RPTX

Company Profile

RPTX logo image Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 129 full-time employees. The company went IPO on 2020-06-19. The firm utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Company Info

REPARE THERAPEUTICS INC

7210 Frederick-Banting, Suite 100

ST-LAURENT QUEBEC H4S 2A1 CA

CEO: Lloyd M. Segal

Employees: 129

RPTX Company Website

RPTX Investor Relations

Phone: 18574127018

REPARE THERAPEUTICS INC / RPTX FAQ

What is the stock price of REPARE THERAPEUTICS INC today?

The current stock price of RPTX is 1.67 USD. The price increased by 0.6% in the last trading session.


What is the ticker symbol for REPARE THERAPEUTICS INC stock?

The exchange symbol of REPARE THERAPEUTICS INC is RPTX and it is listed on the Nasdaq exchange.


On which exchange is RPTX stock listed?

RPTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REPARE THERAPEUTICS INC stock?

9 analysts have analysed RPTX and the average price target is 5.1 USD. This implies a price increase of 205.39% is expected in the next year compared to the current price of 1.67. Check the REPARE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REPARE THERAPEUTICS INC worth?

REPARE THERAPEUTICS INC (RPTX) has a market capitalization of 71.74M USD. This makes RPTX a Micro Cap stock.


How many employees does REPARE THERAPEUTICS INC have?

REPARE THERAPEUTICS INC (RPTX) currently has 129 employees.


What are the support and resistance levels for REPARE THERAPEUTICS INC (RPTX) stock?

REPARE THERAPEUTICS INC (RPTX) has a support level at 1.59. Check the full technical report for a detailed analysis of RPTX support and resistance levels.


Is REPARE THERAPEUTICS INC (RPTX) expected to grow?

The Revenue of REPARE THERAPEUTICS INC (RPTX) is expected to decline by -81.68% in the next year. Check the estimates tab for more information on the RPTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy REPARE THERAPEUTICS INC (RPTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REPARE THERAPEUTICS INC (RPTX) stock pay dividends?

RPTX does not pay a dividend.


What is the Price/Earnings (PE) ratio of REPARE THERAPEUTICS INC (RPTX)?

REPARE THERAPEUTICS INC (RPTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.55).


What is the Short Interest ratio of REPARE THERAPEUTICS INC (RPTX) stock?

The outstanding short interest for REPARE THERAPEUTICS INC (RPTX) is 1.76% of its float. Check the ownership tab for more information on the RPTX short interest.


RPTX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to RPTX. When comparing the yearly performance of all stocks, RPTX is a bad performer in the overall market: 84.08% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RPTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RPTX. RPTX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RPTX Financial Highlights

Over the last trailing twelve months RPTX reported a non-GAAP Earnings per Share(EPS) of -2.55. The EPS decreased by -55.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -84.19%
ROE -99.51%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%46.34%
Sales Q2Q%-100%
EPS 1Y (TTM)-55.49%
Revenue 1Y (TTM)-99.64%

RPTX Forecast & Estimates

9 analysts have analysed RPTX and the average price target is 5.1 USD. This implies a price increase of 205.39% is expected in the next year compared to the current price of 1.67.

For the next year, analysts expect an EPS growth of 10.29% and a revenue growth -81.68% for RPTX


Analysts
Analysts80
Price Target5.1 (205.39%)
EPS Next Y10.29%
Revenue Next Year-81.68%

RPTX Ownership

Ownership
Inst Owners59.19%
Ins Owners0.38%
Short Float %1.76%
Short Ratio2.03